Tesamorelin is FDA-approved. Its own label says it is not a weight-loss drug.

What the label says, in its own words

FDA approved tesamorelin under Biologics License Application 022505 on November 10, 2010.[2] The indication has not widened since. The current EGRIFTA WR prescribing information says the drug “is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy,” and then lists four limitations of use.[1]

The most recent FDA action is easy to over-read. The March 25, 2025 approval that produced EGRIFTA WR is recorded in Drugs@FDA as supplement 20, classified Manufacturing (CMC).[2][11] It was a formulation change, not a new indication and not a new efficacy finding. The label also warns that the two formulations “are not substitutable”: EGRIFTA WR is dosed at 1.28 mg once daily from an 11.6 mg vial, while EGRIFTA SV is a 2 mg-per-vial product with different reconstitution and storage.[1] Every efficacy trial below used 2 mg daily of the original formulation.

Evidence ledger

The randomized human record

This is the unusual part. Most compounds we write about lean on rodent work; tesamorelin does not. Every efficacy figure below comes from randomized, placebo-controlled trials in people, each of them blinded — four say so in the published report, and the registry record for the fifth lists double masking.[13]

Enrollment as reported in each paper.[3][4][5][6][9] Four of these five studied people with HIV; only the last was conducted outside the approved population.

The pivotal trial randomized 412 people to 2 mg of tesamorelin daily or placebo for 26 weeks. Visceral adipose tissue fell 15.2% with tesamorelin and rose 5.0% with placebo; triglycerides and the total-to-HDL cholesterol ratio improved; IGF-1 rose 81.0%.[3][13] The second Phase 3 trial, in 404 patients, reported a 10.9% visceral-fat reduction at six months and roughly 18% in those who continued to twelve.[4] A ClinicalTrials.gov search on August 9, 2026 returned 24 registered tesamorelin studies, 21 of them interventional and two of them Phase 3.[12]

Two 2026 meta-analyses agree — including on what did not move

Two separate author groups pooled this trial set independently in 2026. A meta-analysis in Obesity Research & Clinical Practice included five RCTs and graded certainty with GRADE.[7] A second, in the Journal of the International Association of Providers of AIDS Care, pooled four RCTs covering 909 patients.[8] Their point estimates are close, and so are their null results.

The first meta-analysis reports “no significant reductions in subcutaneous adipose tissue or BMI.”[7] That is not a footnote; it is the same finding the FDA label describes as a weight-neutral effect, arrived at independently.[1] The 2010 trial had already reported the pattern in a single study: trunk fat, waist circumference and waist-hip ratio improved with no change in limb or abdominal subcutaneous fat.[4]

What the trials measured, then, is a shift in where fat sits and how much lean mass is retained — measured by CT and DXA — rather than a fall in body weight. A reader who buys tesamorelin expecting the scale to move is not being contradicted by fringe opinion; they are being contradicted by the manufacturer's own FDA-approved labeling.

The effect appears to depend on continuing to take it

The 2010 study is the only one designed to answer the durability question, and it answered it directly. After six months, participants on tesamorelin were re-randomized: half continued, half switched to placebo, with everyone still blinded. Those who continued reached roughly 18% visceral-fat reduction at twelve months. In those who switched, the initial six-month improvements in visceral fat “were rapidly lost.”[4]

No trial in this set tested a fixed course followed by a drug-free period and found the benefit held. The evidence supports a maintained effect during continuous daily use, and nothing beyond that.

Outside the approved population, the record thins out fast

One randomized, double-blind, placebo-controlled trial has tested tesamorelin in HIV-negative people: 60 abdominally obese adults with reduced GH secretion, dosed for 12 months in 2012. Visceral fat changed by −16 cm² with tesamorelin against +19 cm² with placebo, carotid intima-media thickness and triglycerides improved, and again there was no significant effect on abdominal subcutaneous fat.[9] That is a real result in a real population. It is also 60 people, fourteen years ago, in a trial that selected for reduced growth-hormone secretion, and it has not produced an approval in the intervening years.

The most recent human trial outside the fat-reduction question was null. A 2025 Phase 2 study randomized 73 virally suppressed people with HIV and abdominal obesity 3:2 to tesamorelin or standard of care for six months. Waist circumference fell more with tesamorelin, by a median 2.7 cm, but the between-group difference in neurocognitive performance was not significant (P = .673), and the authors flagged their own limits: insufficient power, and no placebo arm.[10] A trial that reduces the intended intermediate marker without moving the outcome is exactly the result that gets left out of marketing copy.

On liver fat, the evidence is better but still small. In 61 people with HIV and NAFLD randomized for 12 months, hepatic fat fraction fell 4.1 percentage points more than placebo, a 37% relative reduction.[6][14] A 50-person JAMA trial found a comparable direction.[5] Neither is an approved indication.

The safety section is where a GH-axis drug earns its label

Because tesamorelin raises endogenous growth hormone and IGF-1 — a growth factor — the label carries constraints that have no analogue on a vendor product page. EGRIFTA WR is contraindicated in patients with active malignancy, in pregnancy, in patients with disruption of the hypothalamic-pituitary axis, and in known hypersensitivity.[1]

• Neoplasms. The label directs that any preexisting malignancy be inactive and its treatment complete before starting, and that the drug be discontinued on any evidence of recurrence.[1]
• Elevated IGF-1. The label says the effects of prolonged IGF-1 elevation “are unknown,” and instructs prescribers to monitor IGF-1 and consider stopping on persistent elevation.[1]
• Fluid retention. Edema, arthralgia and carpal tunnel syndrome are named.[1]
• Glucose. The label instructs evaluating glucose before and during therapy. In the JAMA trial, fasting glucose rose more with tesamorelin at two weeks (treatment effect 7 mg/dL, 95% CI 1 to 14), though the six-month difference was not significant.[1][5]
• Tolerability. The pooled analysis of 909 patients reported more discontinuation with tesamorelin, at a risk ratio of 2.25, though the interval crossed no difference (95% CI 0.98 to 5.17, P = .06).[8]

The 2007 trial reported no significant overall difference in adverse events, but did note that more tesamorelin patients withdrew because of one.[3] The 2026 pooled safety picture is arthralgia, myalgia, paresthesia and injection-site erythema, without serious events or glucose disturbance across the pooled trials.[7] That safety record belongs to a monitored trial population using a specific licensed product, at 2 mg daily, for six to twelve months.

Why its neighbours on the shelf are not the same story

Tesamorelin is usually sold beside CJC-1295 , Ipamorelin and Sermorelin , and shoppers reasonably read the group as one category. The registries do not. A ClinicalTrials.gov search on August 9, 2026 returned 24 registered studies for tesamorelin against three for ipamorelin and one for CJC-1295.[12] A DailyMed search the same day returned current FDA prescribing information for tesamorelin — two labels, EGRIFTA WR and EGRIFTA SV — and no current FDA labeling at all for sermorelin, ipamorelin or CJC-1295.[15]

So the honest version cuts both ways. Tesamorelin's evidence is stronger than its shelf-mates', and that evidence still says visceral fat in one clinical population, not body recomposition in healthy adults. Borrowing tesamorelin's trials to vouch for a different GHRH analogue is the same error as borrowing them to vouch for weight loss.

In sport the category is treated as one thing, and prohibited. Growth hormone-releasing factors fall under section S2 of the WADA Prohibited List,[17] and a 2026 analytical paper validating a urine method for anti-doping testing names tesamorelin, sermorelin/CJC-1293 and CJC-1295 as the GHRH analogues it detects, at limits of 0.5 ng/mL or below.[16]

Questions people are asking